• Senior Biotech Executive brings over 25 years of drug development expertise

EPALINGES, Switzerland, June 2, 2015 – Anergis, a company developing novel and proprietary ultra-fast allergy immunotherapeutics, today announced the appointment of Kim Simonsen, MD, as Chief Development Officer. Mr. Simonsen will head Anergis´ global product development from preclinical development to registration, including CMC, clinical development, regulatory affairs and global project management.

Kim Simonsen joins Anergis from Ablynx NV, where he was Chief Operations Officer. Prior to that, he was Senior Director, Global Clinical Development, at ALK Abello A/S, where he led the clinical development of Grazax®, the first marketed grass pollen allergy immunotherapy tablet. From 2000 to 2005, Mr. Simonsen was Chief Executive Officer of the CRO Medicon A/S after having held various clinical development roles at big pharmaceutical companies, e.g. as Medical Director of Novartis Healthcare A/S, Director of Clinical Operations at Novo Nordisk A/S, and as Medical Director and Clinical Expert at Sandoz A/S.

Prior to joining the biopharmaceutical industry in 1986, Mr. Simonsen trained as an MD at Copenhagen University and worked for five years at two different clinics in the Copenhagen area, focusing on internal medicine (gastroenterology, respiratory, cardiology). During his career, Mr. Simonsen has gained extensive experience in clinical drug development, including regulatory affairs, clinical pharmacology, and the design and management of clinical trials and pharmacovigilance. His expertise covers an extensive range of disease indications, incl. allergy immunotherapy, immunology, oncology, rheumatology, and cardiovascular and pulmonary diseases.

“We are delighted that Kim Simonsen is joining our team as Chief Development Officer," said Vincent Charlon, Chief Executive Officer of Anergis. “With our leadproduct due to enter Phase III next year and with several novel COP allergy immunotherapeutics reaching clinical stages shortly, Mr. Simonsen´s outstanding track record will be a critical asset for Anergis.”

"Anergis has built an exceptional pipeline of ultra-fast allergy immunotherapeutics and has already reported highly promising clinical data with its lead product," said Kim Simonsen. "I am looking forward to supporting and accelerating the global development of Anergis’ innovative product pipeline."

Contact

  • Biopôle III, Route de la Corniche 9B
    CH-1066 Epalinges
  • Email:
Top

This website uses cookies to ensure you get the best experience on our website.